Heart Disease :: Raising HDL may limit heart disease progression
For people with low levels of “good” (HDL) cholesterol and coronary disease, treatment aimed at increasing HDL levels is worthwhile, researchers report.
Placebo
Mucositis :: Palifermin – Kepivance – to treat mucositis with cancer treatments
The Food and Drug Administration (FDA) approved a new intravenous biologic product, palifermin (trade-name Kepivance) to help reduce the chance that certain cancer patients, those with blood cancers undergoing chemotherapy and radiation in preparation for bone marrow transplants, will develop mucositis. Palifermin also shortens the duration of the condition.
Multiple Sclerosis :: Natalizumab – antibody treatment for Multiple Sclerosis
FDA today licensed a new biologic approach to treat patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of symptom flare-ups or exacerbations of the disease. MS is a chronic, often disabling disease of the brain and spinal cord.
Balanitis :: Inflammation of the head of the penis and foreskin
Inflammation of the head of the penis and foreskin. The disorder can be caused by a bacterial infection, a fungal infection or an allergic reaction. It may also be due to a sexually transmitted infection, such as trichomoniasis. A tighter than normal foreskin may also increase the risk of infection by preventive effective cleaning of the head of the penis. Men with Diabetes Mellitus are more susceptible to the condition. More common in children also.
OCD :: Psychotherapy for youth with obsessive compulsive disorder
Children and adolescents with Obsessive Compulsive Disorder (OCD) respond best to a combination of both psychotherapy and an antidepressant, a major clinical trial has found. Supported by the National Institutes of Health’s (NIH) National Institute of Mental Health, the study recommends that treatment begin with cognitive behavior therapy (CBT), either alone or with a serotonin reuptake inhibitor (SSRI) antidepressant.
Diabetes :: Cymbalta drug to manage diabetic pain
The U.S. Food and Drug Administration has approved Cymbalta, a drug for managing pain associated with diabetic peripheral neuropathy.
Depression :: Psychotherapy effective in adolescents with depression
A clinical trial of 439 adolescents with major depression
has found a combination of medication and psychotherapy to
be the most effective treatment.
Depression :: Overactive emotion-regulating brain circuit
A brain imaging study by the NIH’s National Institute of
Mental Health (NIMH) has found that an emotion-regulating
brain circuit is overactive in people prone to depression –
even when they are not depressed. Researchers discovered
the abnormality in brains of those whose depressions
relapsed when a key brain chemical messenger was
experimentally reduced.
New Drug for treatment of Alcoholism
FDA approved the drug Campral (acamprosate), for treating alcohol dependent individuals seeking to continue to remain alcohol-free after they have stopped drinking. Campral may not be effective in patients who are actively drinking at the start of treatment, or in patients who abuse other substances in addition to alcohol.
Hyperhidrosis :: Botulinum – Botox to treat severe underarm sweating
FDA has approved Botulinum Toxin Type A (Botox) to treat severe underarm sweating known as primary axillary hyperhidrosis that cannot be managed by topical agents such as prescription antiperspirants. Botox has already been approved for several other purposes. Today?s approval allows the product?s manufacturer, Allergan, Inc., Irvine, Calif., to market Botulinum Toxin Type A for this new indication.